Infants with Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
An extended NVP plus ZDV dual regimen administered to infants for 14… may leads to higher infants with any Severe Adverse Events compared with an extended NVP regimen administered to infants (low certainty).
1 finding from 1 review
Infants with Probably Related Severe Adverse Events · Breastfeeding infants of HIV‐infected mothers
It is very uncertain whether an extended NVP plus ZDV dual regimen administered to infants for 14… changes infants with Probably Related Severe Adverse Events compared with an extended NVP regimen administered to infants (very low certainty).
1 finding from 1 review
Global state: recovery (assessed by symptom remission over a specified time period, as defined by study) · recent‐onset psychosis
It is very uncertain whether extended specialised early intervention (SEI) teams changes global state: recovery (assessed by symptom remission over a… compared with standard SEI teams plus treatment (very low certainty).
1 finding from 1 review
Service use: disengagement from services(assessment varied) · recent‐onset psychosis
Extended specialised early intervention (SEI) teams may leads to lower service use: disengagement from services(assessment varied) compared with standard SEI teams plus treatment (low certainty).
1 finding from 1 review
Service use: admission to psychiatric hospital (assessed by proportion admitted at end of treatment) · recent‐onset psychosis
Extended specialised early intervention (SEI) teams showed no clear difference in service use: admission to psychiatric hospital at end of treatment… compared with standard SEI teams plus treatment (low certainty).
1 finding from 1 review
Service use: number of days in psychiatric hospital (assessed by mean number of days in hospital at end of treatment) · recent‐onset psychosis
1 finding from 1 review
Mental state: global psychotic symptoms, average endpoint score on specific symptoms mental state scale(assessed by structured interview) · recent‐onset psychosis
1 finding from 1 review
Adverse effects/events: death ‐ all‐cause mortality(assessed by patient records) · recent‐onset psychosis
Extended specialised early intervention (SEI) teams showed no clear difference in adverse effects/events: death ‐ all‐cause mortality(assessed by… compared with standard SEI teams plus treatment (low certainty).
1 finding from 1 review
Functioning: average endpoint score on specific functioning scale(assessed by structured interview) · recent‐onset psychosis
1 finding from 1 review
VTE‐related mortality4 · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in VTE‐related mortalitya compared with placebo (low certainty).
1 finding from 1 review
Recurrent VTEc · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in recurrent VTEc compared with placebo (moderate certainty).
1 finding from 1 review
Major bleedinge · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in major bleedinge compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortalityg · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in clinically relevant non‐major bleedingh compared with placebo (low certainty).
1 finding from 1 review
Strokei · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in strokei compared with placebo (low certainty).
1 finding from 1 review
Myocardial infarction · patients with unprovoked venous thromboembolism
Extended prophylaxis showed no clear difference in myocardial infarction compared with placebo (low certainty).
1 finding from 1 review
Sustained virological response · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Relapse · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes relapse compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
End of treatment response (ETR) · participants with detectable HCV RNA after 12 weeks of treatment with pegylated interferon and ribavirin, but with >= 2 log viral…
It is very uncertain whether extended peginterferon plus ribavirin treatment for 72 weeks changes end of treatment response (ETR) compared with standard peginterferon plus ribavirin treatment (very low certainty).
1 finding from 1 review
Sustained virological response · participants with detectable HCV RNA after four weeks of treatment with pegylated interferon and ribavirin
Extended peginterferon plus ribavirin treatment for 72 weeks may leads to higher sustained virological response (SVR) compared with standard peginterferon plus ribavirin treatment (low certainty).
1 finding from 1 review